摘要:
A reduction purification method of a nitrogen oxide-containing exhaust gas by contacting said nitrogen oxide-containing exhaust gas with a catalyst in an oxidative atmosphere in which an excess amount of oxygen is present and in the presence of a least one reducing agent selected from the group consisting of a hydrocarbon and an oxygen-containing organic compound, wherein said catalyst comprises an alumina having supported thereon (a) tin and (b) at least one selected from the group consisting of ruthenium, palladium, rhodium and indium.
摘要:
A reduction purification method of a nitrogen oxide-containing exhaust gas by contacting said nitrogen oxide-containing exhaust gas with a catalyst in an oxidative atmosphere in which an excess amount of oxygen is present and in the presence of at least one reducing agent selected from the group consisting of a hydrocarbon and an oxygen-containing organic compound, wherein said catalyst comprises an alumina having supported thereon (a) tin and (b) at least one selected from the group consisting of ruthenium, palladium, rhodium and indium.
摘要:
A process for removing nitrogen oxide from exhaust is disclosed, comprising contacting exhaust containing nitrogen oxide with an alumina catalyst which contains not more than 0.5% by weight of an alkali metal and/or an alkaline earth metal and has a total pore volume of from 0.48 to 1.2 cm.sup.3 .multidot.g.sup.-1 with 0.26 to 0.6 cm.sup.3 .multidot.g.sup.-1 of the total pore volume being formed of pores of not greater than 80 .ANG. or has a volume of pores formed of pores of not greater than 60 .ANG. of from 0.06 to 0.2 cm.sup.3 .multidot.g.sup.-l and which may have supported thereon tin in an oxidative atmosphere containing excess oxygen in the presence of a hydrocarbon or an oxygen-containing organic compound.
摘要:
Disclosed is a sustained-release preparation which is prepared by shaping a granule comprising a blood coagulation factor Xa inhibitor and a mixture of at least two hydrophilic polymers. Also disclosed is a pharmaceutical composition comprising a combination of the sustained-release preparation and an immediate release preparation comprising a blood coagulation factor Xa inhibitor. It becomes possible to provide a controlled release preparation comprising a blood coagulation factor Xa inhibitor for the prevention or treatment of thrombosis, which can control the activity of blood coagulation factor Xa for a long term and is excellent in convenience and compliance. It is also becomes possible to provide a method for producing the controlled release preparation.
摘要:
The solid preparation of the present invention aims at providing a solid preparation superior in the stability during production and preservation even when a poorly water-soluble substance having a low melting point is contained in a large amount, and also superior in the disintegration property and release property of a poorly water-soluble substance having a low melting point, after oral administration, and is characterized by the following 1) to 3): 1) containing a poorly water-soluble substance having a low melting point, a saccharide, and a cellulose selected from a crystalline cellulose and a low-substituted hydroxypropylcellulose, 2) a saccharide/cellulose weight ratio exceeding 2, and 3) a cellulose content of not less than 5 wt %.
摘要:
D-mannitol having a specific surface area of not less than about 1 m2/g is disclosed. The D-mannitol shows improved compressibility and is useful as an excipient.
摘要:
A process for advantageously producing tablets having an improved release property and an excellent stability to change with time is provided. The process is for producing tablets containing a morphinan compound represented by the Formula (I) below or pharmaceutically acceptable acid addition salt thereof and an acidic substance such as fumaric acid, maleic acid or adipic acid, and characterized in that the morphinan compound or a pharmaceutically acceptable acid addition salt thereof is granulated by wet granulation together with (an) excipient(s) prior to adding the acidic substance thereto.
摘要:
A medical drug, in particular, solid preparations containing a medicinal ingredient with high tendency toward gelation, characterized by simultaneously containing a surface modifier and an acid or base. This characteristic realizes improvement to the disintegration easiness, production efficiency and stability of the solid preparations containing the above medicinal ingredient.
摘要:
A catalyst composition for the hydrotreatment of hydrocarbon oils is disclosed. The composition comprises at least one metal compound having hydrogenating activity belonging to a Group VIB or Group VIII carried on a carrier comprising 2-35% by weight of zeolite and 98-65% by weight of alumina or an alumina-containing substance, wherein, (A) said alumina or alumina-containing substance (1) has a mean pore diameter of 60-125 angstrom and (2) contains the pore volume of which the diameter falls within .+-.10 angstrom of the mean pore diameter of 70-98% of the total pore volume, (B) said zeolite (3) has a mean particle size of 6 .mu.m or smaller and (4) contains particles of which the diameter is 6 .mu.m or smaller of 70-98% of all zeolite particles. It has both high hydrodesulfurization and high cracking capabilities at the same time, and can selectively crack the heavy fractions which have once been hydrotreated, yielding lighter fractions.
摘要:
A catalyst composition for the hydrogenation of heavy hydrocarbon oil, where the catalyst composition comprises at least one active ingredient for hydrogenation supported on a porous alumina carrier and has the following characteristics: (1) the total volume of the pores therein is from 0.4 to 1.0 ml/g; (2) the mean pore diameter of pores having a pore diameter of from 5 to 400 .ANG. is from 60 to 140 .ANG.; (3) the volume of pores having a pore size within .+-.25% of the mean pore diameter of pores having a pore diameter of from 5 to 400 .ANG. is from 60 to 98% of the volume of pores having a pore diameter of from 5 to 400 .ANG.; (4) the volume of pores having a pore diameter of from 400 to 5000 .ANG. is from 2 to 9% of the total volume of the entire pores; (5) the ratio (mm.sup.2 /mm.sup.3) of the outer surface area of a molded catalyst powder to the volume thereof is from 4 to 8; and (6) all points in the interior of the molded catalyst particle are positioned within 0.05 to 0.6 mm from the outer surface thereof. A process for producing the catalyst composition is also disclosed. Further, a process for hydrogenating heavy hydrocarbon oil, which comprises contacting the heavy hydrocarbon oil with the catalyst composition in the presence of hydrogen is disclosed.